胆囊癌的靶向治疗研究进展  

Research advances of targeted therapy for gallbladder cancer

作　　者：张宇[1] 吴向嵩[1] 龚伟[1] 储冰峰[1] Zhang Yu;Wu Xiangsong;Gong Wei;Chu Bingfeng(Department of General Surgery,Affiliated Xinhua Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China)

机构地区：[1]上海交通大学医学院附属新华医院普外科,上海200092

出　　处：《腹部外科》2023年第4期256-260,共5页Journal of Abdominal Surgery

基　　金：国家自然科学基金(81974371,82172628,82173048)。

摘　　要：胆囊癌是胆道系统中常见的恶性肿瘤之一,其发病率逐年增加。由于早期症状缺乏特异性,大多数病人在临床诊断时已处于中晚期,失去了根治性手术的机会,导致总体预后较差。作为精准医疗时代的代表性治疗模式,分子靶向治疗具有特异性强、毒副作用小等优势。目前,胆囊癌的分子靶点主要集中在表皮生长因子受体、人表皮生长因子受体-2、血管内皮生长因子等方面。然而,相关研究仍缺乏大样本临床研究的支持,因此需要进一步探索更多的靶点和生物学标志物,以实现个体化的靶向治疗。Gallbladder cancer is one of the most common malignant tumors in biliary system and its incidence is rising yearly.Due to a non-specificity of early symptoms,most patients are already in a middle-to-late stage when they are clinically diagnosed.Thus an opportunity of radical surgery is lost so that there is a poor overall prognosis.As a representative of precision medicine,molecular targeted therapy has such advantages as high specificity and low toxic side effects.Currently molecular targets for GC are focused upon epidermal growth factor receptor,human epidermal growth factor receptor-2 and vascular endothelial growth factor.However,related studies still lack the support of large-sample clinical studies so that more targets and biological markers should be further explored to achieve individualized targeted therapy.

关 键 词：胆囊癌 分子靶点 靶向治疗 

分 类 号：R735.8[医药卫生—肿瘤]